Skip to main content

Zaltrap Side Effects

Generic name: ziv-aflibercept

Medically reviewed by Drugs.com. Last updated on Feb 27, 2024.

Note: This document contains side effect information about ziv-aflibercept. Some dosage forms listed on this page may not apply to the brand name Zaltrap.

Applies to ziv-aflibercept: intravenous solution.

Serious side effects of Zaltrap

Along with its needed effects, ziv-aflibercept (the active ingredient contained in Zaltrap) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ziv-aflibercept:

More common

Less common

Rare

Incidence not known

Other side effects of Zaltrap

Some side effects of ziv-aflibercept may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to ziv-aflibercept: intravenous solution.

Cardiovascular

Very common (10% or more): Hypertension (41%)

Common (1% to 10%): Arterial thromboembolic events (ATE) (e.g., transient ischemic attack, cerebrovascular accident, angina pectoris)

Postmarketing reports: Cardiac failure, ejection fraction decreased[Ref]

Dermatologic

Very common (10% or more): Palmar-plantar erythrodysesthesia syndrome (11%)

Common (1% to 10%): Skin hyperpigmentation[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (69%), stomatitis (50%), abdominal pain (27%), abdominal pain upper (11%)

Common (1% to 10%): Fistulas (anal, enterovesical, enterocutaneous, colovaginal, intestinal sites), dehydration, oropharyngeal pain, hemorrhoids, rectal hemorrhage, proctalgia

Uncommon (0.1% to 1%): GI hemorrhage, toothache[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection

Hematologic

Very common (10% or more): Leukopenia (78%), neutropenia (67%), thrombocytopenia (35%), hemorrhage (38%)[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity[Ref]

Immunologic

Very common (10% or more): Infections (46%)

Common (1% to 10%): Immunogenicity[Ref]

Metabolic

Very common (10% or more): Anorexia (32%), weight loss (32%)

Postmarketing reports: Osteonecrosis of the jaw[Ref]

Nervous system

Very common (10% or more): Headache (22%)

Uncommon (0.1% to 1%): Reversible posterior leukoencephalopathy syndrome (RPLS)[Ref]

Other

Very common (10% or more): Fatigue (48%), dysphonia (25%), asthenia (18%)

Uncommon (0.1% to 1%): Compromised wound healing[Ref]

Renal

Very common (10% or more): Proteinuria (62%), serum creatinine increased (23%)[Ref]

Respiratory

Very common (10% or more): Epistaxis (28%), dyspnea (12%)

Common (1% to 10%): Rhinorrhea, nasopharyngitis[Ref]

Hepatic

Very common (10% or more): AST increased (62%), ALT increased (50%)[Ref]

References

1. Product Information. Zaltrap (ziv-aflibercept). sanofi-aventis. 2012.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.